A phase 1/2 trial of ISM3412 in advanced solid tumours, run by InSilico Medicine Hong Kong Limited, now recruiting.
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06414460 by InSilico Medicine Hong Kong Limited, with 146 participants planned, started 2025-04-25 and due to reach its primary completion in 2028-03-31. Interventions recorded: ISM3412.
Shares Insilico Medicine and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.